IRF4 as an Oncogenic Biomarker for Hematological Malignancies
Journal Title: Journal of Oncobiomarkers - Year 2013, Vol 1, Issue 1
Abstract
The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is crucial for lymphocyte development. Importantly, IRF4 has potent oncogenic and transforming properties, and its intimate interaction with lymphoid and myeloid malignancies has been increasingly recognized. In general, IRF4 exerts its function by transcriptionally regulating a pool of genes pivotal for cell development, oncogenesis and immune response. In clinical practice, IRF4 serves as an important prognosis and diagnosis marker for certain types of these malignancies. However, the oncogenic roles of IRF4 in most types of these malignancies and the molecular mechanisms underlying its interaction with them are largely not characterized. Accumulating evidence from cell culture shows that IRF4 regulates differential targets in distinct cancer contexts, depending on the “context-specific” co-regulator(s) associated with it in each setting. These complementary studies with in vitro cell culture systems are a necessary strategy which will provide molecular and mechanistic insights into the specific regulation and function of IRF4 in distinct cancer contexts, and may identify novel interventions specifically targeting IRF4 regulatory network for treatment. This review summarizes the evidence obtained from bench to bed showing the association of IRF4 with various types of hematological malignancies, with emphasis on molecular mechanisms underlying its regulation and its roles in these contexts.
Authors and Affiliations
Shunbin Ning
Keywords
Related Articles
- EP ID EP206202
- DOI 10.13188/2325-2340.1000003
- Views 90
- Downloads 0
Extracellular Domain Mutation of ErbB2 Status in Japanese Lung Cancer Patients
Purpose: The erbB pathway involves a family of tyrosine kinases and has contributed to resistance or sensitivity for chemotherapy in many tumor types. Somatic mutations of the erbB family receptor gene at kinase domain w...
Low Cell Density Induced Epithelial-Mesenchymal Transition in MCF10A Cell is Regulated by Proteasome Activity
Epithelial-mesenchymal transition (EMT) is a key process in tumor progression and metastasis. Previous studies have shown that MCF10A human mammary epithelial cells undergo EMT when cultured at low cell density, but...
Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer
mTOR is a serine/threonine kinase and plays a critical role in mammalian cell growth, survival, and metabolism. mTOR is present in two cellular complexes: mTORC1 and mTORC2. Dysregulation of the mTOR pathway has been rel...
Diets and Risk of Cancer
A new study is providing further evidence about the potentially life-threatening danger of drinking soda on a daily basis. Large, long-running epidemiological studies have also concluded that there is indeed a link betwe...
Involvement of Sphingosine Kinases/Sphingosine-1-Phosphate (S1P)/S1P Receptors in Breast Cancer Subtypes
There is emerging evidence suggesting sphingolipids as critical regulators of cancer development and progression. Sphingolipids are potent bioactive lipids involved in fundamental biological processes including cell prol...